Tulba, Sherwin O.

HRN: 23-82-88  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/06/2023
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
10/06/2023
10/12/2023
IVTT
2.25 G
Q8
Brain Abscess
Waiting Final Action 

Indication:  EmpiricEmpirical Escalation    Type of Infection:  Central Nervous System    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: